Literature DB >> 21131943

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.

Patrick R Kenny, Daniel E Brady, Dawn M Torres, Linda Ragozzino, Naga Chalasani, Stephen A Harrison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21131943     DOI： 10.1038/ajg.2010.363

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  30 in total

Review 1.  Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.

Authors:  Gerhard H Scholz; Holger Fleischmann
Journal:  Ther Adv Endocrinol Metab       Date:  2014-10       Impact factor: 3.565

2.  Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

Authors:  Thuy-Anh Le; Rohit Loomba
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

3.  The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

Authors:  Lisa B Van Wagner; Mary E Rinella
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

4.  An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Romina Lomonaco; Janet Chen; Kenneth Cusi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 5.  Pharmacotherapy for Nonalcoholic Fatty Liver Disease.

Authors:  Samer Gawrieh; Naga Chalasani
Journal:  Semin Liver Dis       Date:  2015-09-17       Impact factor: 6.115

Review 6.  Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.

Authors:  Zeynel Abidin Ozturk; Abdurrahman Kadayifci
Journal:  World J Hepatol       Date:  2014-04-27

Review 7.  Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.

Authors:  Chao-Lin Li; Lu-Jie Zhao; Xin-Li Zhou; Hui-Xiao Wu; Jia-Jun Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

Review 8.  Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

Review 9.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

10.  Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery.

Authors:  Peng-Yu Yang; Huafei Zou; Elizabeth Chao; Lance Sherwood; Vanessa Nunez; Michael Keeney; Esi Ghartey-Tagoe; Zhongli Ding; Herlinda Quirino; Xiaozhou Luo; Gus Welzel; Guohua Chen; Parminder Singh; Ashley K Woods; Peter G Schultz; Weijun Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.